(NAGE) Niagen Bioscience Inc Company Overview

What does Niagen Bioscience do?

Niagen Bioscience, Inc. trades on the Nasdaq Capital Market under NAGE and commercializes nicotinamide riboside chloride, or NR, a vitamin B3 form used to support cellular NAD+. It sells a branded healthy-aging supplement, supplies proprietary ingredients to manufacturers and medical-compounding channels, and invests in pharmaceutical research. The March 2025 renaming from ChromaDex made Niagen both the company name and core technology brand.

Which products and customers define the business?

The consumer engine is Tru Niagen, a finished dietary supplement sold through the company’s own e-commerce sites, Amazon, selected retailers, healthcare-practitioner channels and international distributors. The ingredient engine sells food-grade Niagen to supplement and food manufacturers and pharmaceutical-grade Niagen to U.S. FDA-registered 503B outsourcing facilities and certain international compounding pharmacies. Those facilities compound prescription intravenous and injectable formulations marketed through the Niagen Plus ecosystem. A separate Pharmaceuticals segment is developing an NAD+ precursor candidate for rare, advanced aging-related diseases but generated no revenue in Q1 2026.

The company’s official corporate site frames the purpose as improving healthspan by restoring and optimizing NAD+ levels. For analysis, the important point is not the slogan but the operating consequence: management is concentrating capital on a single scientific platform that can be monetized through consumer products, ingredient licensing and supply, clinical channels, and potentially prescription therapeutics.

How does Niagen Bioscience make money?

Niagen has two current revenue engines and one development option. Consumer Products earns revenue from direct and distributor sales of Tru Niagen; e-commerce provides pricing and customer control but requires substantial marketing. Ingredients earns revenue from bulk sales to food, supplement and compounding partners, with lower consumer selling costs but lumpier orders and mix shifts between food-grade and pharmaceutical-grade material.

Which revenue stream matters most?

What does Niagen Bioscience’s latest quarter show?

The latest available official reporting period is Q1 2026, the three months ended March 31, 2026. The headline was continued profitability, but the quality of that profit requires adjustment. Net sales rose 3% to $31.5 million, or about 5% when the divested Reference Standards business is excluded from both periods. Gross margin held at 63.5%, yet operating income fell because sales and marketing, R&D and general-and-administrative costs increased. Reported net income rose to $6.3 million largely because the sale of the Reference Standards segment generated a $4.8 million gain.

What changed inside the revenue mix?

The strongest underlying channel signal was e-commerce: sales rose 14% to $19.2 million, offsetting lower Watson and other B2B sales of $3.2 million. Food-grade Niagen reached $7.3 million, while pharmaceutical-grade Niagen declined to $0.9 million from $1.0 million. The company’s Q1 2026 earnings release and Form 10-Q therefore point to a strategic tension: demand is still growing, but management is spending ahead of near-term sales to protect the brand and develop new channels.

Which turning points shaped Niagen Bioscience today?

Niagen’s history is a transition from analytical chemistry services to a focused NAD+ platform. It explains the current consumer, ingredient and pharmaceutical ambitions, the importance of intellectual property, and the strategic meaning of the February 2026 divestiture.

1. 1999
   The predecessor built an analytical reference standards business. That capability created scientific credibility, but it ultimately became peripheral to the larger Niagen opportunity.
2. 2008
   The public-company merger created ChromaDex Corporation, establishing the listed vehicle that later funded commercialization and intellectual-property development.
3. 2013
   Food-grade Niagen was commercialized as a dietary and food ingredient, converting NR research into a scalable B2B product.
4. 2016–2017
   Nasdaq listing and the acquisition of Healthspan Research supported the launch of Tru Niagen, shifting the model from ingredient supplier toward a branded direct-to-consumer platform.
5. 2024
   Niagen Plus introduced pharmaceutical-grade Niagen into clinic and compounding channels, creating a medical-adjacent extension with higher regulatory exposure.
6. 2025
   The company renamed itself Niagen Bioscience and changed the ticker to NAGE, aligning corporate identity with the core platform. FY2025 sales reached $129.4M and net income reached $17.4M.
7. 2026
   Reference Standards was sold for about $6.0M, sharpening focus on consumer products, ingredients and pharmaceutical development. A new $50.0M at-the-market facility also expanded financing flexibility.

What did the 2026 divestiture change?

Reference Standards contributed $3.1 million of FY2025 revenue and $0.7 million of gross profit. Its sale removed a lower-margin, noncore activity and generated a $4.8 million Q1 2026 gain. Because Q1 still includes partial segment and transition-services revenue, researchers should emphasize continuing Niagen-related revenue in future comparisons.

The current structure and turning points are described in the FY2025 Form 10-K, which is the most useful official source for the company’s business evolution, segment definitions and risk factors.

What gives Niagen Bioscience a competitive advantage?

Niagen’s moat is not based on manufacturing scale alone. It is a combination of owned and exclusively licensed patents, regulatory authorizations, a large external research network, a branded consumer product, and experience translating one molecule across ingredient, retail and clinical channels. The company reports more than 300 research collaborations, over 500 peer-reviewed studies on NR science, more than 525 published human clinical studies related to NAD+, and 41 published human clinical trials involving proprietary Niagen.

How durable are the science and intellectual-property advantages?

Food-grade Niagen has completed two FDA new dietary ingredient notifications and has been notified as generally recognized as safe. It also has authorizations or approvals in several international jurisdictions. Pharmaceutical-grade Niagen is eligible for use by FDA-registered 503B outsourcing facilities, expanding the platform beyond conventional supplements. The company continues to add patent protection, including a 2025 U.S. patent covering composition-of-matter claims for certain NR salt forms. These protections do not eliminate competition, but they can raise legal, scientific and regulatory barriers for close substitutes.

Where is the moat less secure?

Consumers can switch among supplements with low friction, and perceived efficacy can be influenced by price, marketing or competing scientific claims. Patent scope can be challenged, licensed rights can expire, and alternative NAD+ precursors can compete without copying Niagen exactly. The company also relies on third parties for manufacturing and distribution. Its strongest moat elements therefore support trust and differentiation, but they do not create the near-absolute lock-in found in a network platform or regulated utility.

The 2025 patent announcement illustrates the company’s continuing effort to extend protection around next-generation NR forms rather than relying solely on older licensed patents.

Who are Niagen Bioscience’s main competitors?

Niagen competes across consumer wellness, ingredients and pharmaceuticals. Consumer rivals sell NR, nicotinamide mononucleotide and other NAD+-related supplements. Ingredient rivals compete for formulation slots and partner budgets. Pharmaceutical competition includes biotechnology companies, large drug developers, universities and research institutions pursuing similar disease targets.

How does Niagen position itself against rivals?

The filings name Elysium Health in historical patent and commercial litigation, showing that rivalry involves both markets and intellectual property. The official annual-report archive defines competition through quality, efficacy, science, brand, price, distribution and compliance. Supplier power is meaningful because NR supply is concentrated; buyer power varies by channel; substitutes are numerous; and credible scientific entry requires more than ordinary supplement marketing.

How financially strong is Niagen Bioscience?

At March 31, 2026, Niagen held $66.5 million of cash against $32.0 million of total liabilities, with $114.3 million of assets and $82.3 million of equity. It reported no line-of-credit borrowings. Liquidity supports inventory, brand investment and R&D, although purchase commitments, deferred patent consideration and potential equity issuance remain important.

Why did cash flow weaken in Q1 2026?

Operating cash flow was a $1.2 million outflow, compared with a $7.9 million inflow a year earlier. Inventory consumed $3.6 million and trade receivables consumed $3.4 million. Receivables reached $13.1 million and inventory reached $24.0 million at quarter-end. Three customers represented 52.2% of receivables, although management said the concentration largely reflected purchase timing and noted that a $1.3 million Asian retail partner balance was collected by the end of April. This is a classic working-capital warning: accounting profit can look healthy while cash is tied up in stock and customer balances.

How is management allocating capital?

The July 2026 at-the-market prospectus creates an unusual capital-allocation contrast: the company bought back stock in Q1, then established the ability to issue up to $50 million of stock. No full draw is guaranteed, but researchers should track actual issuance because it can fund expansion while diluting existing holders. The company has never paid a cash dividend and does not expect one in the foreseeable future.

Who owns Niagen Bioscience stock, and why does governance matter?

Niagen has one class of common stock and no disclosed dual-class voting structure. The ownership profile is nevertheless concentrated. The 2026 proxy reported 79.6 million shares outstanding as of April 27, 2026. Solina Chau beneficially owned 19.3 million shares, or 24.23%, making her the largest disclosed shareholder. CEO Rob Fried beneficially owned 4.7 million shares, or 5.65%, while founder and chairman Frank Jaksch beneficially owned 2.8 million shares, or 3.47%. Directors and current executive officers as a group beneficially owned 8.5 million shares, or 10.00%.

What does the board structure signal?

The governance interpretation is mixed but understandable. Concentrated ownership can support patient capital and strategic continuity, especially for a science-led platform. It can also reduce the practical influence of smaller shareholders. Options are material: the April 2026 proxy attributed 3.0 million exercisable-within-60-days option shares to the CEO and 4.5 million to directors and executives as a group. The 2026 proxy statement is therefore essential for understanding both voting influence and potential dilution.

Where could Niagen Bioscience grow next?

The most credible near-term opportunity is continued scaling of the existing Niagen franchise rather than an immediate pharmaceutical breakthrough. FY2025 showed what operating leverage can look like when consumer and ingredient revenue grow together: total sales rose 30%, gross profit rose 35%, and sales and marketing declined as a share of revenue to 27% from 30%. Q1 2026 then showed the opposite side of the model, with slower sales growth and renewed spending. The central question is whether those investments restore faster growth.

Which growth vectors are already visible?

The company’s investor-relations overview summarizes the FY2025 step-up in sales, margin, earnings and cash. The opportunity case depends on turning that stronger base into repeatable growth rather than treating one exceptional year as a permanent run rate.

What risks could change Niagen Bioscience’s outlook?

Niagen’s risks are interconnected. Product concentration amplifies scientific, regulatory and reputational exposure. Third-party manufacturing links supply performance to customer trust. International distribution adds partner and regulatory uncertainty, while pharmaceutical development introduces clinical risk to a business that only recently became consistently profitable.

Which risk is most operationally important?

W.R. Grace is especially important because it supplies food-grade NRC and holds patents related to its crystalline form. A disruption or unfavorable renewal could affect Tru Niagen and ingredient customers. Inventory protects service levels but consumes cash; it reached $24.0 million in Q1 2026.

Why does Niagen Bioscience’s business model matter for valuation?

A valuation model should separate the existing commercial platform from the pharmaceutical option. The consumer and ingredient businesses can be analyzed through revenue growth, gross margin, marketing efficiency, working-capital needs and cash conversion. The pharmaceutical segment should not be valued as if approval were certain; it is better treated through probability-weighted scenarios or excluded from a conservative base case until milestones become clearer.

Which KPIs should drive a DCF?

FY2025 provides a high-growth reference: $129.4 million of revenue, 64.3% gross margin, $17.4 million of net income and $13.5 million of operating cash flow. Q1 2026 provides a normalization point: 3% reported growth, 5% continuing-business growth, a 5.0% operating margin and negative operating cash flow. Neither period should be extrapolated mechanically, and the small, concentrated platform warrants a higher discount rate than a mature consumer-staples business.

The Q1 2026 earnings presentation is especially useful for separating e-commerce, B2B and ingredient revenue, while the 10-K provides the risk and cost structure needed for long-term assumptions.

What is the key takeaway from Niagen Bioscience analysis?

Niagen Bioscience has evolved into a focused NAD+ platform with a real commercial base, a strong gross-margin profile, meaningful cash, no outstanding line-of-credit borrowings and a differentiated scientific story. The company’s importance comes from its attempt to control multiple layers of the same market: proprietary ingredient science, branded consumer products, partner formulations, clinical channels and pharmaceutical development.

The strongest evidence supporting the story is operational rather than promotional. FY2025 revenue grew 30% to $129.4 million, ingredient sales grew 45%, Tru Niagen sales grew 27%, and operating cash flow reached $13.5 million. The main caution is that Q1 2026 growth slowed, operating expenses rose 26%, operating income fell to $1.6 million, and net income was boosted by a one-time divestiture gain. Cash remained strong, but working capital absorbed funds.